» Articles » PMID: 15932882

Biophysical Characterization of the Interaction Domains and Mapping of the Contact Residues in the XPF-ERCC1 Complex

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2005 Jun 4
PMID 15932882
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

XPF and ERCC1 exist as a heterodimer to be stable and active in cells and catalyze DNA cleavage on the 5'-side of a lesion during nucleotide excision repair. To characterize the specific interaction between XPF and ERCC1, we expressed the human ERCC1 binding domain of XPF (XPF-EB) and the XPF binding domain of ERCC1 (ERCC1-FB) in Escherichia coli. Milligram quantities of a heterodimer were characterized with gel filtration chromatography, an Ni(2+)-NTA binding assay, and analytical ultracentrifugation. Cross-linking experiments at high salt concentrations revealed that XPF interacts with ERCC1 mainly through hydrophobic interactions. XPF-EB was also shown to homodimerize in the absence of ERCC1. NMR cross-saturation methods were applied to map the residues involved in formation of the XPF-EB.XPF-EB homodimer and the XPF-EB.ERCC1-FB heterodimer. Helix H3 and the C-terminal region of XPF-EB were either within or in close proximity to the homodimer interface, whereas the ERCC1-FB binding site of XPF-EB was distributed across helix H1, a small part of H2, H3, and the C-terminal region, most of which exhibited large changes in chemical shift upon ERCC1 binding. The XPF-EB heterodimeric interface is larger than the XPF-EB homodimeric one, which could explain why XPF has a stronger affinity for ERCC1 than for a second molecule of XPF. The XPF binding sites of ERCC1 were located in helices H1 and H3 and in the C-terminal region, similar to the involved surface of XPF. We used cross-saturation data and the crystal structure of related proteins to model the two complexes.

Citing Articles

Nano-delivery of a novel inhibitor of ERCC1-XPF for targeted sensitization of colorectal cancer to platinum-based chemotherapeutics.

Mehinrad P, Abdelfattah A, Sadat S, Shafaati T, Elmenoufy A, Jay D Drug Deliv Transl Res. 2025; .

PMID: 39878858 DOI: 10.1007/s13346-024-01782-9.


mA-Modified SNRPA Controls Alternative Splicing of ERCC1 Exon 8 to Induce Cisplatin Resistance in Lung Adenocarcinoma.

Fan W, Huang J, Tian F, Hong X, Zhu K, Zhan Y Adv Sci (Weinh). 2024; 11(47):e2404609.

PMID: 39555714 PMC: 11653629. DOI: 10.1002/advs.202404609.


A novel algorithm for the virtual screening of extensive small molecule libraries against ERCC1/XPF protein-protein interaction for the identification of resistance-bypassing potential anticancer molecules.

Ghazy S, Oktay L, Durdagi S Turk J Biol. 2024; 48(2):91-111.

PMID: 39051064 PMC: 11265927. DOI: 10.55730/1300-0152.2686.


Noise Stress Abrogates Structure-Specific Endonucleases within the Mammalian Inner Ear.

Guthrie O Int J Mol Sci. 2024; 25(3).

PMID: 38339024 PMC: 10855171. DOI: 10.3390/ijms25031749.


Modulation of ERCC1-XPF Heterodimerization Inhibition Structural Modification of Small Molecule Inhibitor Side-Chains.

Weilbeer C, Jay D, Donnelly J, Gentile F, Karimi-Busheri F, Yang X Front Oncol. 2022; 12:819172.

PMID: 35372043 PMC: 8968952. DOI: 10.3389/fonc.2022.819172.